Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 09, 2023 16:03 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences

VANCOUVER, British Columbia, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, announced that its partner, Neurocrine...
November 08, 2023 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Topline data from XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder on track for late November to mid-December XEN1101 Phase 3 epilepsy program continues to progress with X-TOLE2...
November 01, 2023 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Corporate Update

VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third...
October 09, 2023 16:15 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Announces Publication of Results from XEN1101 Phase 2b “X-TOLE” Clinical Trial in Peer-Reviewed Journal Article in JAMA Neurology

VANCOUVER, British Columbia, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the medical journal JAMA...
October 06, 2023 08:30 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit

VANCOUVER, British Columbia, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
September 14, 2023 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals to Present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit

VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
September 12, 2023 16:30 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive Disorder

VANCOUVER, British Columbia, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will host an...
September 04, 2023 08:30 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress

New interim data from ongoing Phase 2b X-TOLE open-label extension demonstrates improvement in overall quality-of-life (QoL) when compared to baseline Clinically important improvements seen for...
August 31, 2023 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals to Present at the Wells Fargo 2023 Healthcare Conference

VANCOUVER, British Columbia, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
August 09, 2023 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Last patient enrolled in XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder with topline data expected in late November to mid-December Continued progress across all XEN1101 Phase 3...